In summary, we have revealed a novel lncRNA, TMEM92‐AS1, which has potential for use as a biomarker to predict OS and DFS in GC patients, and which has oncogenic properties by promoting the proliferation and migration of GC cells. Here, TMEM92 is linked to gastric cancer.